ARTICLE DOWNLOAD

Clinical impact of statin therapy on vasospastic angina: data from a Korea nation-wide cohort study

10$
ARTICLE DOWNLOAD

Clinical impact of statin therapy on vasospastic angina: data from a Korea nation-wide cohort study

10$

Won-Woo Seo, Sang-Ho Jo, Sung Eun Kim, Seung Hwan Han, Kwan Yong Lee, Sung Ho Her, Min-Ho Lee, Sung Seek Cho & Sang Hong Baek

Abstract

The effect of statin therapy on reducing adverse cardiovascular events in vasospastic angina (VSA) has been inconsistent. Therefore, we investigated the association between statin therapy and adverse cardiovascular events in a large, prospective VSA cohort. The Variant Angina Korea registry consecutively enrolled 2960 patients suspected VSA. Among them, we included 1713 patients who were diagnosed with VSA based on coronary provocation test. We divided the patients into the statin (n = 744) and no-statin group (n = 914) according to the medication prescribed at discharge. The primary outcome was a composite of cardiac death, acute coronary syndrome, and new-onset life-threatening arrhythmia during a 3-year follow-up period. The primary outcome occurred in 32 patients (4.3%) in the statin and 28 patients (3.1%) in the no-statin group. In Kaplan–Meier analysis before and after propensity score matching, there was no significant difference in the cumulative incidence of primary outcomes between both groups. Multivariate Cox regression analysis demonstrated that the focal type of VSA was independent predictor of primary outcomes, but statin therapy was not. Furthermore, the lack of benefit of statin therapy for primary outcomes was consistently observed across the statin intensity and spasm characteristics. In conclusion, the present study demonstrated that statin therapy did not reduce adverse cardiovascular events in patients with VSA.

Only units of this product remain
Year 2020
Language English
Format PDF
DOI 10.1007/s00380-020-01579-z